ArticleDrug delivery and translational research2026
Redispersible nanoalum-adjuvanted hepatitis B vaccine microneedles with enhanced immunogenicity.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Nanoalum has been widely investigated as an advanced aluminum-based adjuvant; however, its performance in solid vaccine formulations remains poorly understood because administration depends on reconstitution after storage and delivery. Here, a hepatitis B surface antigen (HBsAg) vaccine was formulated with nanoalum, freeze-dried, and delivered using a powder-attached microneedle array patch (P-MAP). Formulations were screened based on redispersion in PBS after lyophilization to identify a lead composition (HBsAg: Alhydrogel: PAA: Trehalose = 1:5:5:50, w/w/w/w; F12), and the effects of preparation pH (7.4 vs. 5.6) were evaluated. The optimized formulation maintained a nanoscale dispersed state after PBS reconstitution (< 250 nm), whereas PEG-substituted and PAA-free formulations showed severe aggregation (> 2 μm). When administered as liquid intradermal injections, preparation pH produced minimal differences in immune responses. In contrast, clear divergence emerged following freeze-drying and P-MAP delivery. The pH 5.6 formulation (G9) generated the highest IFN-γ ELISpot response among all P-MAP groups while maintaining strong HBsAg-specific IgG responses and an increased IgG2a/IgG1 tendency. The PAA-free formulation (G10), which exhibited poor redispersion after reconstitution, produced reduced and more variable antibody responses. Notably, formulations displaying nanoscale redispersion consistently outperformed aggregated formulations in both humoral and cellular immune responses. These findings demonstrate that post-lyophilization redispersion is a critical quality attribute for nanoalum-containing solid vaccine formulations and that formulation conditions governing redispersion can substantially influence immune outcomes following P-MAP delivery.
Indexed as
Identifiers
42365188What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.